Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422981 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
A Phase 2 study of Mild Cognitive Impairment, So Stated, sponsored by Allon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 17
- Study locations
NCT00422981: Completed Phase 2 study of Mild Cognitive Impairment, So Stated, sponsored by Allon Therapeutics.
NCT00422981 is a Phase 2 study of Mild Cognitive Impairment, So Stated that has completed, run by Allon Therapeutics. The registered enrollment target is 144 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422981, a Phase 2 study of Mild Cognitive Impairment, So Stated, has completed, sponsored by Allon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AL-108
Study Locations (17)
Florida
- Meridien Research - Brooksville
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Clinical Neuroscience Solutions - Orlando
- Meridien Research - Tampa
- Stedman Clinical Trials - Tampa
- Clinical Research Center of Indian River Medical Center - Vero Beach
California
- Collaborative Neuroscience Network - Garden Grove
- Synergy Research - National City
- Pacific Research Network, Inc - San Diego
Arizona
- Pivotal Research - Peoria
Illinois
- Comprehensive Neuroscience - Hoffman Estates
New Jersey
- The Memory Enhancement Center of America - Long Branch
New York
- SPRI Clinical trials - Brooklyn
North Carolina
- Memory Assessment and Research Services - Wilmington
Ohio
- Neurology & Neuroscience Center of Ohio - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
What the finished NCT00422981 record still lists
NCT00422981 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Mild Cognitive Impairment, So Stated appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00422981 lists 17 locations in 10 states (Florida, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT00422981 about?
NCT00422981 is a clinical study titled "Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment". The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
What is the current status of trial NCT00422981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2007-01. Estimated completion is 2008-01.
What conditions does trial NCT00422981 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, So Stated.
What interventions are being tested in trial NCT00422981?
The interventions under investigation include: Placebo (DRUG), AL-108 (DRUG).
Who is sponsoring clinical trial NCT00422981?
This trial is sponsored by Allon Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00422981 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00422981's enrollment target sits among peer trials
144 500th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia